Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Almotriptan Malate
Almotriptan · 2 trials · 1 indication
Headache pain free is defined as a decrease in baseline pain intensity from severe, moderate or mild to no pain, without the use of supplemental pain medication and/or anti-emetic medication (including a second dose of study medication) within 2 (or 24) hours of first dose of study medication. Sustained pain free is defined as pain free at 2 and 24 hours without the use of supplemental pain medication and/or anti-emetic medication (including a second dose of study medication) within 24 hours.
| Arm | Type | Description |
|---|---|---|
| Almotriptan Malate | EXPERIMENTAL | Patients will take one 12.5 mg almotriptan malate tablet by mouth after the onset of migraine headache pain |
| Name | Type | Description |
|---|---|---|
| Almotriptan Malate | DRUG | Patients will take one 12.5 mg almotriptan malate tablet by mouth after the onset of migraine headache pain |
Inclusion Criteria: * Have a history of migraine for at least one year * Have an average of 1 - 14 migraines per month for the 6 months prior to study entry * Able to swallow oral medication * Able to complete a headache diary * Only taking one migraine preventive medication and on the same dose of...
Top 5 of 8 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 13 | PHASE3 | Atogepant, Ubrogepant, MEDI0618 |
| Pfizer Inc. | PFE | 11 | PHASE3 | Rimegepant, Zavegepant |
| Eli Lilly and Company | LLY | 2 | PHASE3 | Galcanezumab |
| Amgen Inc. | AMGN | 2 | PHASE3 | Erenumab |
| Evommune, Inc. | EVMN | 1 | PHASE2 | EVO756 |
Almotriptan is used to treat migraine headaches. It belongs to the triptan class of medicines and is taken to relieve acute migraine attacks. The clinical program described here focused on treating migraine in adolescents aged 12 years and older, studied across two completed Phase 3 trials.
Almotriptan targets the serotonin receptors HTR1B, HTR1D, and HTR1F, where it acts as an agonist. By activating these receptors, the small molecule is designed to produce its effects in the treatment of acute migraine. These receptor targets define its pharmacology within the triptan class.
Almotriptan is developed by Johnson & Johnson, which trades under the ticker JNJ. The company sponsored the clinical development program for the drug in migraine, including the Phase 3 studies conducted in adolescents. Almotriptan is a small molecule developed within Johnson & Johnson's neurology portfolio.
Almotriptan has been studied in Phase 3 clinical development for migraine. Two Phase 3 trials have been completed, and no trials are currently active. The program enrolled a total of 1,313 participants across those completed studies, which were randomized and double blind.
Almotriptan has been evaluated in two completed Phase 3 trials. NCT00257010 was a one-year study in adolescents assessing long-term safety of almotriptan malate for migraine headaches, enrolling 447 participants in the United States. NCT00210483 studied three dosage strengths of almotriptan malate in acute migraine in adolescents, enrolling 866 participants.
Yes, almotriptan malate is the same drug as almotriptan. Almotriptan malate is the salt form used in the clinical trials and in the studied product, including the Phase 3 adolescent migraine studies. The two names refer to the same active agent rather than to different medicines.